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Although this segment of management should not be neglected (e.g. prompt and accurate diagnosis, early initiation of treatment in family practice, faster transportation, better organization and distribution of adequately staffed and well equipped interventional units), the bulk of the problem lies at the other end of the clinical spectrum -in unsatisfactory prevention. The EURASPIRE III results (4) show that during the past decade the prevalence of obesity among coronary patients in Europe has increased from 25% to 38%, and that of diabetes from 7.4% to 28%, while smoking and hypertension rates remained unchanged, i.e. approx. 20 % and 60%, respectively. Which are the obstacles on the path to effective primary prevention of CHD, i.e. to adequate protection of apparently healthy, younger people against adverse responsibility for careless and hazardous life-style is left out in the cold, but in the case of misfortune instead of silent suffering the health problem is suddenly and vociferously socialized, requesting costly treatment at the expense of solidarity. These inconsistencies in ethics should be corrected if adequate and coherent attitudes towards health care in the community are to be contemplated. 3) Decisive role of risk factors. A number of large-scale investigations, from the Framingham cohort to the recent INTERHEART case-control study (9, 0) , have clearly demonstrated that CHD is uncommon without a concurrent or antecedent exposure to one or several major risk factors. With the clustering of these factors the probability of CHD complications increases exponentially (Table ) . More than twenty years ago our study showed that declaratively appropriate and cost-effective measures for managing arterial hypertension are seldom implemented in daily practice (6) . There is a wide gap between words and deeds, which needs to be bridged both by physicians, patients and the population at large. 2) Ethical issues. From the middle of the past century the human rights movement has been rapidly expanding, this development being expected and understandable after incredible crimes against human dignity committed not only during World War II but also previously and subsequently alike (7). Patient autonomy is respected whenever possible, and the traditional, paternalistic doctor-patient relationship is replaced by a kind of negotiating, mutually agreeable partnership, with informed consent as one of its cornerstones. It seems, however, that modern society is moving towards the other extreme: while striving for human rights, the dues tend to be neglected. Although these components of moral judgment should stay in balance -more rights beget more obligations -the ethics of rights is overwhelming the ethics of responsibilities (8) . It is increasingly overlooked that individual rights are limited by the rights of the neighbours and the community at large, so that current moral judgment is focusing more closely on individual than on collective interest. Personal The former + obesity prej{nji + debelost 68.5
The former + psychosocial factors prej{nji + psihosocialni dejavniki 82.9
Combination of the former six factors + lack of physical activity + inadequate alcohol intake (more than moderate or total abstinence) kombinacija prej{njih {estih dejavnikov + pomanjkanje telesne dejavnosti + neustrezno pitje alkohola (ve~ kot zmerno ali popolna abstinenca) 333.7 Table 2 ). The probability of adverse prognosis was even higher in the presence of additional risk factors; e.g. the prevalence of arterial hypertension among these high-risk children was 46.4%, and that of smoking was even higher, i.e. 5.3% (4). These data send us the following vivid message: a) The incidence of early atherosclerotic complications at young age is low (<5% of the CHD patients), an the prevalence in those patients' offspring among their peers is even lower (<%); b) Some conventional risk factors (e.g. smoking, obesity) are detectable at a glance, while others, such as hyperlipoproteinemia and hypertension, are confidently and cheaply identified in those selected individuals; c) Simple measures, such as dietary advice or smoking cessation programs, and rare, specific interventions (e.g. statins in heterozygous familial hypercholesterolemia) substantially improve the cardiovascular prognosis in these individuals. 6) General measures are underestimated and largely ignored. The effectiveness of well structured counseling on lifestyle modifications has been ascertained beyond any reasonable doubt (5). However, just a minor portion of persons at increased risk quit smoking, decrease body mass and salt intake, adopt a "Mediterranean" diet or engage in adequate exercise for any longer period of time (6, 7). There are several formal reasons for this situation; some pertain to fluid diagnostic criteria (e.g. for the metabolic syndrome) or overlapping guidelines (e.g. misunderstandings about global cardiovascular risk assessment by the Framingham and SCORE tables, although the former is obviously related to morbidity, and the latter to mortality) (8) . However, fundamental are socio-economic and cultural barriers 5,7 which may be overcome by early gentle and persistent education about healthy lifestyles, extending from family to school and involving the whole community. Additional effects may be obtained through legislation and law enforcement (e.g. higher smoking taxation and/or banning). 7) Drug therapy is hastily prescribed in primary prevention. Potent drugs are too often prescribed on the ground of a single laboratory result or blood pressure reading. Such interventions are frequently superfluous because of false positive findings (e.g. white coat hypertension, biological variation, laboratory flaw) or could be postponed while waiting for the results of effective lifestyle modifications. Moreover, wide implementation of pharmacotherapy in primary prevention bears several burdens: a) Individual prognosis in a low-risk population is only marginally, although statistically significantly, improved by the use of highly effective modern drugs (e.g. statins, ACE inhibitors): the medication must be taken by several hundreds of low-risk individuals for years to benefit just a few; b) The expected side-effects (e.g. angioedema with ACE inhibitors, myopathy with statins), although rare, (incidence rate well below 0.% ) become alarming when legions of apparently healthy individuals are exposed to the intervention; c) The probability of adequate intake of this medication is inversely proportional to subjective ailments, motivation, and the number of people exposed. Noncompliance becomes the rule rather than an exception, particularly if the subjects are inadequately informed and motivated; d) This approach is extremely expensive, and could absorb up to 25-50% of all the funds available to health service (9) . Pharmacoeconomic analyses are invaluable in addressing these issues, but other variables, such as political feasibility and social acceptability, must be kept in mind as well (20 (23) . It is self-evident that results of unconvincing clinical trials should not be implemented in practice. However, even the messages given by large, well-designed, randomized clinical trials with hard end-points (mostly hospital-based and including very sick inpatients) must not be literally extrapolated to family practice i.e. to mostly ambulatory and less sick, outpatients, since two opposite extremes of the same nosologic spectrum are at stake. Then, again, the treatment may have worse effects than the disease itself, as argued in paragraph 7. 9) Pharmacotherapy is underused in secondary CHD prevention. In contrast to primary prevention which shows a tendency to overprescribe pharmacotherapy, in secondary prevention, protective drugs are quantitatively and qualitatively underprescribed for individuals at substantially higher risk. Again, the reasons are manifold, from differences in opinions and attitudes encountered in various countries and even regions, to the neglect of convincing scientific evidence. This is sometimes due to fear of possible adverse effects, which, considering a favorable risk/benefit ratio in this case, are quite acceptable (24, 25) . However, there are differences in the level of therapeutic gain between the available interventions because of unequal intrinsic efficacy and dissimilar patient characteristics. This concept is best illustrated with the number of patients who require treatment to prevent one event (NNT). The relative cost/effectiveness reasoning is clearly illustrated in the following example. Suppose that a country may afford about eight million € to give simvastatin, one of the best known statins, in a daily dose of 20 mg to 25,000 people with increased CHD risk. If such treatment is given to high-risk individuals (4S study criteria) it can save some 90 lives per year; if the treatment is offered to mediumrisk individuals (HPS study criteria), it can save about 90 persons, and if the treatment is offered to lower-risk individuals (WOSCOPS or ASCOT-LLA criteria) some 69 deaths can be prevented with the same investment (9) . Many coronary patients may need a complicated drug regimen of variable therapeutic gain (Table 3) , consisting possibly of aspirin (acetysalicylic acid), a β-adrenergic blocker, a statin, an ACE inhibitor, a diuretic, an aldosterone antagonist (e.g. eplerenone), a nitrate, some digoxin, a fish-oil formulation, and other ingredients (26) . In order to lower the prevalence of coronary risk factors in the population, instead of sophisticated technology, invasive procedures and expensive medications, many education efforts coupled with human understanding, persuasion, and common sense are desperately needed. These issues can best be addressed in a personalized, family practice. Hypertension, smoking or weight gain embody many behavioural components that are not easily addressed by formal medical therapy alone. Family medicine has a unique opportunity for behavioral modification at the individual and public health levels, based on empathy, role modeling, and personal skills in communication and education. It should be remembered that specialist training in family medicine was introduced in Croatia half a century ago (27) and that at the time, Croatian family practice professionals were among the world's leading experts in the field. Instead of treating diseases, family medicine helps sick individuals by enhancing the quality of their life; instead of depersonalized, industrialized services, it offers human understanding, instead of high technology that benefits a few, it delivers efficient care to many, and instead of fee for service, it ensures comprehensive care. After identifying the level of coronary risk, family physician must give pertinent, evidence-based information to a patient (or a small group of patients). He/she must answer the patients' questions, allow time for data interpretation, and, after a while, schedule a discussion about their views, problems, and steps to be taken. Such a task takes a lot of time, dedication and commitment to be effective. Family physicians must be adequately remunerated for their services and unburdened of huge capitation rates (presumably not more than ,500 under care in Croatia) and cumbersome administration, setting aside two hours per day for preventive and educational purposes. That such amendments are feasible was recently shown in the field of minor surgery (28) . Intrinsic to family medicine are certain attitudes that are not readily taught at medical schools: the need to compromise, humility, tolerance and acceptance of different values (29) . The most important teaching method is acting as a role model, in other words being an exemplar of decorum (i.e. a propriety of appearance and behaviour) that manifest one's inner virtues, e.g. in order for a physician in the field of preventive cardiology to be persuasive, he/she must not be an authoritative, obese smoker. Preventive programs should be cost-effective. However, humanism is about quality and not quantity. It is hardly defined and measured in a quantitative manner. Fine qualitative research, followed by quantitative studies, should be done to convince the politicians of the benefits and advantages of investing in family practice (29) . In this perspective, we foresee the solution for the stagnant or worsening circumstances in preventive cardiology. Finally, we would mention some additional relevant problems emerging in everyday practice, which a competent family physician must be able to solve individually, on the spot:
• At which level a risk factor becomes a disease (e.g. millimeters of mercury for blood pressure or millimoles per liter for cholesterol, glucose or uric acid)? • Which are the pros and cons of labeling a newly discovered, at-risk but apparently healthy, symptomless person as sick (e.g. hypertension, hyperlipidemia)? • Should the patient be scared, encouraged or something else? • When it is appropriate to refer a patient for a specialist consultation? • How to overcome the apparent conflict between general measures -which as a rule are ignored -, and drug therapy which is accepted and even requested, mostly for episodic, on/off and ineffective treatment? In other words: how to bridge the gap between scientific evidence and crude reality?
